Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Healing & Tissue Repair

LL-37

Human cathelicidin antimicrobial peptide

Also known as: Cathelicidin hCAP-18 fragment

Evidence: Preclinical only Disclaimer: Critical Not FDA-approved

Mechanism & research context

Endogenous antimicrobial peptide with immunomodulatory and wound-healing activity studied in vitro and in animal models.

Safety flags

0 flags

No curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.

Research papers

16 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

Clinical trials

21 records
  • Live search Live search

    Live ClinicalTrials.gov search: LL-37

    Condition: See live results

    Open on ClinicalTrials.gov ↗
  • NCT01308619 PHASE4 COMPLETED

    A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules

    Condition: Rosacea

    Sponsor: Galderma R&D

    Open on ClinicalTrials.gov ↗
  • NCT01689441 PHASE2 COMPLETED

    Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis

    Condition: Severe Sepsis or Septic Shock

    Sponsor: Brigham and Women's Hospital

    Open on ClinicalTrials.gov ↗
  • NCT01689779 PHASE3 COMPLETED

    Effect of High-dose Cholecalciferol Supplementation on Perioperative Vitamin D Status in Colorectal Surgery Patients

    Condition: Hypovitaminosis D

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT01702974 PHASE2 COMPLETED

    Immune Reconstitution in HIV Disease Using Antimicrobial Treatment With Vitamin D and Phenylbutyrate

    Condition: HIV Infection

    Sponsor: Karolinska Institutet

    Open on ClinicalTrials.gov ↗
  • NCT01951352 NA COMPLETED

    Effects of Surfactants on the Innate Immune System

    Condition: Healthy

    Sponsor: University of California, San Diego

    Open on ClinicalTrials.gov ↗
  • NCT02367612 PHASE2 COMPLETED

    Fermented Milk on the Appearance of Common Winter Infectious Diseases

    Condition: Acute Gastroenteritis; Upper Respiratory Tract Infections

    Sponsor: Federico II University

    Open on ClinicalTrials.gov ↗
  • NCT02945683 NA COMPLETED

    Randomized Controlled Trial to Evaluate the Beneficial Effects of a Probiotic Food Supplement in Children With Atopic Dermatitis

    Condition: Atopic Dermatitis

    Sponsor: Noos S.r.l.

    Open on ClinicalTrials.gov ↗
  • NCT03038932 COMPLETED

    Integrated Extreme Trait Analysis to Understand the Etiology of Eczema Herpeticum (ADRN-06)

    Condition: Eczema Herpeticum

    Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

    Open on ClinicalTrials.gov ↗
  • NCT03270709 PHASE1 TERMINATED

    Effect of High-Dose Vitamin D3 on Alveolar Macrophage Function, LL-37, and Oxidative Stress in Smokers and Non-Smokers With and Without HIV

    Condition: HIV/AIDS; Vitamin D Deficiency; Smoker Lung

    Sponsor: Emory University

    Open on ClinicalTrials.gov ↗
  • NCT03434249 NA COMPLETED

    Studio Clinico Randomizzato Per Valutare l'Efficacia Del Bifidobacterium BB-12® Nel Trattamento Delle Coliche Infantili

    Condition: Infantile Colic; Colic, Infantile

    Sponsor: SOFAR S.p.A.

    Open on ClinicalTrials.gov ↗
  • NCT04098562 PHASE2 UNKNOWN

    The Efficacy of LL-37 Cream on Aerobic Bacteria Colonization Pattern, Inflammation Response: Interleukin 1α (IL-1α) and Tumor Necrosis Factor α (TNF-α), and Healing Rate of Diabetic Foot Ulcers

    Condition: Diabetic Foot Ulcer

    Sponsor: Fakultas Kedokteran Universitas Indonesia

    Open on ClinicalTrials.gov ↗
  • NCT04404335 COMPLETED

    The Role of Anti-inflammatory Cytokines and Antimicrobial Peptide LL-37 Biomarkers in the Treatment of Periodontal Disease.

    Condition: Periodontal Diseases; Periodontitis

    Sponsor: Universidad Rey Juan Carlos

    Open on ClinicalTrials.gov ↗
  • NCT04722640 PHASE4 UNKNOWN

    Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity

    Condition: Psoriasis

    Sponsor: Istituto Clinico Humanitas

    Open on ClinicalTrials.gov ↗
  • NCT04861493 COMPLETED

    Cathelicidin LL-37 Levels in the Gingival Crevicular Fluid and the Saliva of Smokers and Non-smokers With Stage III,IV Periodontitis :An Observational Study

    Condition: Smoking Reduction

    Sponsor: Cairo University

    Open on ClinicalTrials.gov ↗
  • NCT05208099 NOT_YET_RECRUITING

    Study of the Immunomodulation of the Immune Response in Hidradenitis Suppurativa and in Vitro and ex Vivo Evaluation of a New Therapeutic Strategy (IMOHS)

    Condition: Hidradenitis Suppurativa

    Sponsor: Lille Catholic University

    Open on ClinicalTrials.gov ↗
  • NCT05398770 NA COMPLETED

    Randomized Clinical Trial on the Effect of Vitamin D Supplement Prior to Non-surgical Periodontal Therapy: a Feasibility Trial

    Condition: Periodontitis; Periodontal Diseases; Periodontal Inflammation; Inflammation; Inflammation Gum; Vitamin D

    Sponsor: University of Tromso

    Open on ClinicalTrials.gov ↗
  • NCT07129486 NOT_YET_RECRUITING

    Intermittent-Hypoxia Inhibits Neutrophil Extracellular Traps Formation: Role of Cathelicidins

    Condition: Obstructive Sleep Apnea (OSA)

    Sponsor: Kun-Ta Chou

    Open on ClinicalTrials.gov ↗
  • NCT07414030 COMPLETED

    Evaluation of the Relationship Between Salivary Antimicrobial Peptides and Severe Early Childhood Caries in Turkish Children

    Condition: Severe Early Childhood Caries; Dental Caries

    Sponsor: Bezmialem Vakif University

    Open on ClinicalTrials.gov ↗
  • NCT07490587 PHASE2 RECRUITING

    To Investigate the Effects of Bifidobacterium Animalis Subsp. Lactis XLTG11 on Growth and Development, Incidence of Allergy and Immune Function in Infants

    Condition: Healthy Children

    Sponsor: Min-Tze LIONG

    Open on ClinicalTrials.gov ↗
  • NCT07505329 NA NOT_YET_RECRUITING

    An Intervention Study in Healthy Infants Aged 0-6 Months With Probiotics Lacticaseibacillus Rhamnosus LRa05 (LRa05) and Bifidobacterium Animalis Subsp. Lactis BLa80 (BLa80) vs. Placebo, for Promoting Gut Microbiome Development.

    Condition: Less Than 3 Months Old; Healthy Infants

    Sponsor: University College Cork

    Open on ClinicalTrials.gov ↗

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for LL-37 yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of LL-37, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for LL-37. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.